Concourse Financial Group Securities, Inc. Arcellx, Inc. Transaction History
Concourse Financial Group Securities, Inc.
- $1.67 Billion
- Q4 2024
Number of Shares
0
Previous 0
NaN%
Holding current value
$0
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding ACLX
# of Institutions
223Shares Held
44.7MCall Options Held
434KPut Options Held
433K-
Paradigm Biocapital Advisors LP New York, NY4.37MShares$265 Million12.7% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$227 Million20.37% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$213 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY3.48MShares$211 Million8.84% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.33MShares$202 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $2.66B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...